Auris Health, Inc., part of Johnson & Johnson Medical Devices Companies, today announced that physicians have performed over 1,000 bronchoscopic procedures using the Monarch™ Platform. Auris gained FDA clearance for diagnostic and therapeutic bronchoscopic procedures on the Monarch Platform in the Spring of 2018.
“We are grateful for the physicians who routinely use the Monarch Platform who aim to detect lung cancer more accurately and earlier, and helped us reach this exciting and significant milestone,” said Eric Davidson, Vice President Marketing and Sales. “The rapid adoption of the technology demonstrates that Monarch helps overcome the limitations of current, manual bronchoscopic technology in the diagnosis of lung disease.”
The Monarch Platform is designed to help physicians diagnose lung nodules when they are small and more easily treated. It has a dedicated camera and instrument channel that allow continuous vision throughout the entire procedure, enabling physicians to biopsy lung nodules that historically have been very difficult to reach.
Auris’ goal is to enable more-accurate diagnosis, and eventually treatment, of small and hard-to-reach nodules in the periphery of the lung. Lung cancer is the leading cause of cancer deaths worldwide, representing more patient deaths each year than prostate, breast, and colon cancers combined. Auris’ goal is to transform the diagnosis of lung disease and save lives. This is only the beginning.